BridgeBio Pharma, Inc. Interest Payable, Current
BridgeBio Pharma, Inc. (BBIO) had Interest Payable, Current of $16.53 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:InterestPayableCurrent · last filed 2026-08-10
- 2026-06-30: Interest Payable, Current $16.53M.
- 2026-03-31: Interest Payable, Current $5.19M.
- 2025-12-31: Interest Payable, Current $14.41M.
- 2025-09-30: Interest Payable, Current $4.25M.
| Period end | Interest Payable, Current | Interest Payable, Current as first filed |
|---|---|---|
| 2026-06-30 | $16.53M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $5.19M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $14.41M 10-Q · filed 2026-08-10 | |
| 2025-09-30 | $4.25M 10-Q · filed 2025-10-29 | |
| 2025-06-30 | $14.41M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $14.41M 10-Q · filed 2026-05-07 | $4.25M 10-Q · filed 2025-04-29 |
| 2024-12-31 | $11.06M 10-K · filed 2026-02-24 | |
| 2024-09-30 | $3.41M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $11.35M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $3.87M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $17.76M 10-K · filed 2025-02-20 | |
| 2023-06-30 | $17.52M 10-Q · filed 2023-08-03 | |
| 2022-12-31 | $17.50M 10-K · filed 2024-02-22 | |
| 2020-12-31 | $600.00K 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |